| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.097 | 0.003 |
| mRNA | methylstat | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.16 | 0.004 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.004 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.005 |